Pharvaris
IPOPioneering Science for Patient Choice
Public · Zug, Switzerland · Founded 2015 · $216.0M raised
- Headquarters
- Zug
- Employees
- 51–200
- Founded
- 2015
- Business Model
- B2B
- Website
- pharvaris.com
- Total Funding
- $216.0M
- Last Round
- $70.0M Private EquityJun 2023
- Rounds
- 3
- Type
- Public
About
Pharvaris is a late-stage biopharmaceutical company developing novel oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks. Its lead asset, deucrictibant, is in two pivotal Phase 3 trials (CHAPTER-3 for prophylaxis and RAPIDe-3 for on-demand treatment), aiming to deliver injectable-like efficacy with the convenience of oral administration.
Summary
Pharvaris is a Biotech company based in Zug, Switzerland, founded in 2015. It has raised $216.0M in total across 3 rounds, most recently a $70.0M Private Equity round in Jun 2023.
Tech & App Stack
4 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jun 2023
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Similar Companies
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Alphabet-backed biotechnology company researching biology of aging and developing interventions t...
BridgeBio makes targeted treatments for genetic diseases.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...